title: Rofecoxib-associated upper gastrointestinal bleed: a case report.
abstract: To our knowledge, this is the first clinical report of a rofecoxib-associated upper gastrointestinal hemorrhage. We urge caution in prescribing rofecoxib to patients with risk factors for peptic ulcer disease and recommend limiting the dose to 25 mg per day for these patients.
authors.affiliation: Pain Management Service, Box 1192, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029, USA.
authors.forename: Gordon M
authors.initials: GM
authors.lastname: Freedman
authors.forename: Joel M
authors.initials: JM
authors.lastname: Kreitzer
authors.forename: Ruchi
authors.initials: R
authors.lastname: Badola
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D003424:Crohn Disease / Q000150:complications; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications; D013450:Sulfones
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib